We are announcing the appointment of a new CEO Dr. Janet Hoogstraate. Janet is a distinguished leader within the biopharmaceutical sector and this move follows the company’s strategic merger with Valneva Sweden’s Clinical Trial Manufacturing Unit.
Janet will succeed Helena Strigård who in a short time navigated NorthX through several important milestones, including global promotion of NorthX’ services and the recent merger.
Press release here:
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
Amarna Therapeutics, a privately held biotechnology company specializing in transformative gene therapies, is pleased to announce its strategic collaboration with NorthX Biologics, a leading biologics manufacturing partner. This partnership represents ...
Neogap Therapeutics, a Swedish clinical-stage biotechnology company, has entered a strategic collaboration with NorthX Biologics, a leading CDMO, to advance manufacturing strategies for Neogap’s personalised cancer cell therapy. Supported by ...
Abera Bioscience AB (“Abera” or “the Company”) has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal vaccine, Ab-01.12, towards clinical trials. ...